New UK Joint Venture Bridges Gap between Top Universities and Big Pharmas

27/01/2016 - 3 minutes

AstraZeneca, GlaxoSmithKline, Johnson & Johnson and the 3 world-leading universities (Imperial College London, University College London and the University of Cambridge) have joined forces  to found the ‘Apollo’ Bridge.

stevenage_catalyst_apolo_gsk_biotech_ucl_imperialThis pioneering new joint venture, the Apollo Therapeutics Fund, will support the translation of ground-breaking academic science from within these universities into innovative new medicines for a broad range of diseases.

Each of the three industry partner companies (AstraZeneca, Glaxo Group and J&J Innovation) will contribute £10M (€13.15M) over 6 years to the venture.

The technology transfer offices (TTOs) of the three university partners – Imperial Innovations, Cambridge Enterprise and UCL Business  – will each contribute a further £3.3M (€4.34M).


The university partners are also located along the M11 Cambridge-London ‘Bioscience Corridor’ which includes the Stevenage Bioscience Catalyst (where Apollo is to be based) and Cell Therapy Catapult.

Related Content

Apollo will be advised by an independent Drug Discovery Team (DDT) of ex-industry scientists,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following: